Abstract
Nitric oxide synthase (NOS) is a dimeric enzyme that catalyses the production of nitric oxide (NO) in the human body. The nitric oxide has been identified as the most interesting and vital mediators for normal and pathological processes, including the regulation of blood pressure, neurotransmission, and macrophage defence system, but the over production of it can be toxic, hence their inhibitors are desired. In this article, the various isoforms of NOS and their roles are described and a detail of the development of their inhibitors has been presented. The inhibitors studied include aminopyridines, iminopiperidines, N-phenylamidines, benzoxazolones, isothioureas, oxazepanes, thiazepanes, diazepanes, 4,5-disubstituted-1,3-oxazolidin-2-imine derivatives, thiazolidines, pyrazoles, pyrazolines, and some others.
Keywords: Nitric oxide synthase (NOS), Nitric oxide synthase inhibitors, aminopyridines, iminopiperidines, N-phenylamidines, benzoxazolones, isothioureas, oxazepanes, thiazepanes, diazepanes, 4, 5-disubstituted-1, 3-oxazolidin-2-imine derivatives, thiazolidines, pyrazoles, pyrazolines
Current Enzyme Inhibition
Title:Advances in Design and Development of Inhibitors of Nitric Oxide Synthases
Volume: 9 Issue: 2
Author(s): Harish Kumar, Satya P. Gupta, Anees A. Siddiqui and Vijay Kumar
Affiliation:
Keywords: Nitric oxide synthase (NOS), Nitric oxide synthase inhibitors, aminopyridines, iminopiperidines, N-phenylamidines, benzoxazolones, isothioureas, oxazepanes, thiazepanes, diazepanes, 4, 5-disubstituted-1, 3-oxazolidin-2-imine derivatives, thiazolidines, pyrazoles, pyrazolines
Abstract: Nitric oxide synthase (NOS) is a dimeric enzyme that catalyses the production of nitric oxide (NO) in the human body. The nitric oxide has been identified as the most interesting and vital mediators for normal and pathological processes, including the regulation of blood pressure, neurotransmission, and macrophage defence system, but the over production of it can be toxic, hence their inhibitors are desired. In this article, the various isoforms of NOS and their roles are described and a detail of the development of their inhibitors has been presented. The inhibitors studied include aminopyridines, iminopiperidines, N-phenylamidines, benzoxazolones, isothioureas, oxazepanes, thiazepanes, diazepanes, 4,5-disubstituted-1,3-oxazolidin-2-imine derivatives, thiazolidines, pyrazoles, pyrazolines, and some others.
Export Options
About this article
Cite this article as:
Kumar Harish, Gupta P. Satya, Siddiqui A. Anees and Kumar Vijay, Advances in Design and Development of Inhibitors of Nitric Oxide Synthases, Current Enzyme Inhibition 2013; 9 (2) . https://dx.doi.org/10.2174/1573408011309020005
DOI https://dx.doi.org/10.2174/1573408011309020005 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular Risk Factors, Vascular Diseases, and Imaging Findings in a Hospital-based Cohort of Mild Cognitive Impairment Types
Current Alzheimer Research Biomarkers in Lone Atrial Fibrillation-An Additional ‘Fine Tuning’ of Risk?
Current Pharmaceutical Design Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets An Insight into the Recent Diabetes Trials: What is the Best Approach to Prevent Macrovascular and Microvascular Complications?
Current Diabetes Reviews Cardiovascular Risk in Patients with Primary Hyperparathyroidism
Current Pharmaceutical Design Inotropic and Vasoactive Drugs in Pediatric ICU
Current Drug Targets Pleiotropic Effects of Statin in Therapy in Heart Failure: A Review
Current Vascular Pharmacology Clinical Pharmacotherapy and Drug Development for Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Pharmacy and Exercise as Complimentary Partners for Successful Cardiovascular Ageing
Current Vascular Pharmacology Characterization of Adipose-Derived Stem Cells: An Update
Current Stem Cell Research & Therapy Insulin Resistance, Oxidative Stress and Cardiovascular Complications: Role of Sirtuins
Current Pharmaceutical Design Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders
Current Signal Transduction Therapy Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design A Ligand-Based Virtual Screening Approach to Identify Small Molecules as hERG Channel Activators
Combinatorial Chemistry & High Throughput Screening Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
Current Clinical Pharmacology Mechanisms Explaining the Influence of Subclinical Hypothyroidism on the Onset and Progression of Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Can microRNAs be Biomarkers or Targets for Therapy of Ischemic Coronary Artery Disease in Metabolic Syndrome?
Current Drug Targets Is the Vascular System a Main Target for Thyroid Hormones? From Molecular and Biochemical Findings to Clinical Perspectives
Current Vascular Pharmacology Vitamin D and Vitamin D Receptor Activators in Treatment of Hypertension and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets